Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      ShangPharma Announces Fourth Quarter and Fiscal Year 2011 Results


      News provided by

      ShangPharma Corporation

      Mar 12, 2012, 06:30 ET

      Share this article

      Share this article


      SHANGHAI, March 12, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2011.

      To help management and investors gain a better understanding of ShangPharma's operating performance, the Company presents certain non-GAAP measures, each of which excludes expenses relating to or the effect of share-based compensation and IPO bonuses. See "About Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Data" below for more information about the non-GAAP financial measures included in this press release.

      Fourth Quarter 2011 Highlights

      • Net revenues increased by 19.0% year-over-year to $30.5 million.
      • Net revenues from China-based customers increased by 208.7% year-over-year to $4.0 million, accounting for 13.0% of total revenues, up from $1.3 million in the fourth quarter of 2010.
      • GAAP gross margin was 32.7%, compared with 32.3% in the fourth quarter of 2010. Non-GAAP gross margin was 34.4%, remaining stable from the fourth quarter of 2010.
      • GAAP operating margin was 7.5%, compared with 3.6% in the fourth quarter of 2010. Non-GAAP operating margin was 13.1% compared with 16.7% in the fourth quarter of 2010, primarily due to higher listed-company related professional fees and increased operating costs related to our expanded facilities.
      • Revenue per employee increased 8.8% year-over-year.

      Full Year 2011 Highlights

      • Net revenues increased by 23.6% year-over-year to $111.6 million, which is within our previously released annual guidance.
      • Net revenues from China-based customers increased by 169.1% year-over-year to $12.1 million.
      • Average revenue per customer for the top-10 customers increased to $6.9 million, compared with $5.7 million in 2010, while revenue from top-10 customers accounted for 61.8% of total revenue, compared with 63.0% in 2010. This was a result of continued efforts to become a preferred business partner of leading global pharmaceutical and biotech companies as well as increased customer-base diversification.
      • GAAP gross margin was 32.3%, compared with 33.4% in 2010. Non-GAAP gross margin was 34.3%, compared with 34.5% in 2010.
      • GAAP operating margin was 8.7%, compared with 11.5% in 2010. Non-GAAP operating margin was 14.2% compared with 15.9% in 2010, primarily due to the continued appreciation of the Renminbi, increased operating costs related to our expanded facilities as well as higher listed company-related professional fees.
      • Revenue per employee increased 12.9% year-over-year.

      Management Comment

      "I am pleased to report that ShangPharma maintained steady top-line growth in the fourth quarter of 2011," said Michael Xin Hui, founder and Chief Executive Officer of ShangPharma. "Our strategic investments in facilities and service quality in 2011 should improve ShangPharma's competitiveness going forward and position us to take a market-leading position in areas such as biologics, biology and integrated drug discovery services projects."

      Mr. Hui continued, "During the year, we continued to diversify our revenue base, with China-based customers growing particularly rapidly. As we expand our offering, we look forward to broadening our existing relationships with multinational clients through cross-selling opportunities. In addition, upgrades to our facilities and staff should help us to win more higher value-added projects."

      William Dai, Chief Financial Officer, added, "While the investments we made in 2011 to upgrade ShangPharma's services offering will bring increased facility related expenses in the near term, greater employee productivity should help reduce pressure on margins. These investments are critical for our strategy to position ShangPharma at the center of China's burgeoning CRO market for the long term, and in 2012, our focus on managing costs and lowering capital expenditures should help ensure positive free cash flow for the full year."

      Fourth Quarter 2011 Results

      Net revenues were $30.5 million, an increase of 19.0% from $25.6 million in the fourth quarter of 2010. Higher volumes from the Company's top customers and greater cross-selling of services were major drivers of this growth.    

      Revenue from customers based in China rose by 208.7%.  The growth came both from local pharmaceutical companies and smaller domestic laboratories, as well as major multinational biotech and pharmaceutical companies' China-based R&D centers.

      Revenue from the Company's top-10 customers increased by 16.6 % compared with the same period last year, and accounted for 62.0% of  total revenue, compared with 63.3% in the same quarter last year. The growth was a result of multinational pharmaceutical companies expanding their scope of work with the Company.

      Net revenues from full-time-equivalent ("FTE")-based services were $22.2 million, an increase of 24.7% from $17.8 million in the fourth quarter of 2010. This was primarily due to higher volumes from the Company's top customers, a larger customer base and expanded service offerings, as well as higher average FTE rates.

      Net revenues from fee-for-service-based services were $8.3 million, an increase of 6.1% from $7.8 million in the fourth quarter of 2010.  This was primarily driven by a continued strong increase in demand from China-based companies, successful service cross-selling and rapid increased demand for services including discovery biology, preclinical development and biologics.

      Gross profit was $10.0 million, an increase of 20.5% from $8.3 million in the fourth quarter of 2010. This was primarily due to an increase in revenues, operational efficiency improvements and lower share-based compensation expenses as a result of the one-time restricted share unit ("RSU") costs charged upon completion of the Company's IPO in the fourth quarter of 2010. These were partially offset by continued appreciation of the Renminbi, changes in service mix, and facility expansion costs, which include less than full utilization of our Fengxian manufacturing facility and the increased rental, depreciation and utility costs related to a new building dedicated to one of our major customers, which was put into use in December 2011, as well as the assumed facilities lease from Charles River as part of the asset acquisition in November 2011.

      Non-GAAP gross profit was $10.5 million, an increase of 18.7% from $8.8 million in the fourth quarter of 2010, primarily due to an increase in revenues and operational efficiency improvements. These were partially offset by the continued appreciation of the Renminbi, changes in service mix and facility expansion costs.

      Gross margin was 32.7%, compared with 32.3% in the fourth quarter of 2010, primarily due to lower share-based compensation expenses as a result of the absence of the one-time restricted share unit ("RSU") costs charged upon completion of the Company's IPO in the fourth quarter of 2010. 

      Non-GAAP gross margin was 34.4%, remaining stable from the fourth quarter of 2010. Operational efficiency improvements were offset by the continued appreciation of the Renminbi, changes in service mix and facility expansion costs. The investments and upgrades to our facilities, such as Fengxian, a new building devoted to one of our major customers and the Charles River asset acquisition are critical in positioning us for future growth and moving up the value chain. Excluding the added facility expansion costs, our non-GAAP gross margin would have been approximately 36.4%, a 200 basis points improvement despite the continued appreciation of the Renminbi.

      Operating expenses (selling and marketing, general and administrative) were $7.7 million, an increase of 4.3% from $7.3 million in the fourth quarter of 2010. This was primarily due to higher listed company-related professional fees and increased operating expenses related to facility expansion costs. These were partially offset by lower share-based compensation expenses as a result of the one-time RSU costs charge upon completion of the Company's IPO in the fourth quarter of 2010 and IPO bonuses accrued in the fourth quarter of 2010.

      Non-GAAP operating expenses were $6.5 million, an increase of 42.4% from $4.6 million in the fourth quarter of 2010. This was primarily due to higher listed company-related professional fees and facility expansion costs.

      Profit from operations was $2.3 million, an increase of 150.1% from $0.9 million in the fourth quarter of 2010, primarily due to an increase in revenues, lower share-based compensation expenses as a result of the absence of the one-time RSU costs charged upon completion of the Company's IPO in the fourth quarter of 2010, and operational efficiency improvements. These were partially offset by the continued appreciation of the Renminbi, changes in service mix, facility expansion costs, and higher listed company-related professional fees. 

      Non-GAAP profit from operations was $4.0 million, a decrease of 6.5% from $4.3 million in the fourth quarter of 2010.  Higher gross profits were offset by higher listed company-related professional fees and increased expenses related to our expanded facilities.

      Operating margin was 7.5%, compared with 3.6% in the fourth quarter of 2010.  This was primarily due to lower share-based compensation expenses as a result of the absence of the one-time restricted share unit ("RSU") costs charged upon completion of the Company's IPO in the fourth quarter of 2010 and operational efficiency improvements. These were partially offset by the continued appreciation of the Renminbi, changes in service mix, facility expansion costs, and higher listed company-related professional fees.

      Non-GAAP operating margin was 13.1%, compared with 16.7% in the fourth quarter of 2010, primarily due to the continued appreciation of the Renminbi, changes in service mix, facility expansion costs, and higher listed company-related professional fees. If the impact of facility expansion costs had been excluded, our non-GAAP operating margin would have been 15.9% despite the continued appreciation of the Renminbi.

      Net income decreased 10.4% year-over-year to $2.3 million. Higher profit from operations was offset by lower other income, such as lower government subsidies, smaller gain on foreign exchange forward contracts and lower investment income.

      Non-GAAP net income was $4.0 million, a decrease of 32.5% from $5.9 million in the fourth quarter of 2010. This was primarily due to lower non-GAAP profit from operations and lower other income。 

      Diluted earnings per ADS were $0.12, which compares with $0.14 in the fourth quarter of 2010.

      Non-GAAP diluted earnings per ADS were $0.21, which compares with $0.32 in the fourth quarter of 2010.

      Fiscal Year 2011 Results

      Net revenues were $111.6 million, an increase of 23.6% from $90.3 million in 2010. This was primarily due to higher volumes from the Company's top customers, greater cross selling of services and growth of the Company's customer-base.    

      Revenue from China-based customers increased by 169.1% to $12.1 million. This was primarily due to increased drug development activities from domestic pharmaceutical and biotech companies and increased R&D investment into China by global pharmaceutical and biotech companies. 

      Revenue from the Company's top-10 customers increased by 21.2% compared with last year, and accounted for 61.8% of total revenue, compared with 63.0% in 2010. This was a result of continued efforts to become a preferred business partner of leading global pharmaceutical and biotech companies as well as increased customer-base diversification.

      Net revenues from full-time-equivalent ("FTE")-based services were $80.7 million, an increase of 23.4% from $65.4 million in 2010. This was primarily due to higher volumes from the Company's top customers, a larger customer base and higher average FTE rates.

      Net revenues from fee-for-service-based services were $30.9 million, an increase of 24.3% from $24.9 million in 2010.   This was primarily driven by a continued strong increase in demand from China-based companies, successful service cross-selling and rapid increased demand for services including discovery biology, preclinical development and biologics.

      Gross profit was $36.1 million, an increase of 19.9% from $30.1 million in 2010. This was primarily due to an increase in revenues and operational efficiency improvements, which were partially offset by continued appreciation of the Renminbi, higher materials costs as a result of changes in service mix and higher share-based compensation expenses.

      Non-GAAP gross profit was $38.2 million, an increase of 22.9% from $31.1 million in 2010. This was primarily due to an increase in revenues and operational efficiency improvements, which were partially offset by the continued appreciation of the Renminbi and higher materials costs as a result of changes in service mix.

      Gross margin was 32.3%, compared with 33.4% in 2010, primarily due to the continued appreciation of the Renminbi, higher material costs as a result of changes in service mix and higher share-based compensation expenses, which were partially offset by operational efficiency improvements. 

      Non-GAAP gross margin was 34.3%, compared with 34.5% in 2010.  Operational efficiency improvements were offset by the continued appreciation of the Renminbi and higher material costs as a result of changes in service mix.

      Operating expenses (selling and marketing, general and administrative) were $26.4 million, an increase of 34.0% from $19.7 million in 2010. This was primarily due to the continued appreciation of the Remnimbi, increased expenses related to expanded facilities, higher share-based compensation expenses and higher listed company-related professional fees.

      Non-GAAP operating expenses were $22.4 million, an increase of 33.5% from $16.7 million in 2010. This was primarily due to the continued appreciation of the Remnimbi, increased expenses related to expanded facilities and higher listed company-related professional fees.

      Profit from operations was $9.7 million, a decrease of 7.0% from $10.4 million in 2010.  An increase in revenues and operational efficiency improvements were offset by the continued appreciation of the Renminbi, increased expenses related to expanded facilities, higher share-based compensation expenses and higher listed company-related professional fees.

      Non-GAAP profit from operations was $15.9 million, an increase of 10.6% from $14.4 million in 2010. Higher gross profits were partially offset by the continued appreciation of the Renminbi, increased expenses related to expanded facilities and higher listed company-related professional fees.

      Operating margin was 8.7%, compared with 11.5% in 2010.  This was primarily due to lower gross margin, continued appreciation of the Renminbi,  increased expenses related to expanded facilities, higher share-based compensation expenses and higher listed company-related professional fees. These were partially offset by operational efficiency improvements.

      Non-GAAP operating margin was 14.2%, compared with 15.9% in 2010, primarily due to lower non-GAAP gross margin, the continued appreciation of the Renminbi, increased operating expenses related to expanded facilities and higher listed company-related professional fees.

      Net income decreased 13.5% year-over-year to $11.2 million. This was primarily due to lower profit from operations and lower other income, including smaller gain on foreign exchange forward contracts and lower income from government subsidies. These factors were partially offset by higher interest income.

      Non-GAAP net income was $17.5 million, an increase of 2.9% from $17.0 million in 2010. This was primarily due to higher non-GAAP profit from operations and was partially offset by lower other income. 

      Diluted earnings per ADS were $0.60, which compares with $0.78 in 2010. 

      Non-GAAP diluted earnings per ADS were $0.93, which compares with $1.07 in 2010.

      Financial Position 

      As of December 31, 2011, the Company had cash and cash equivalents of $38.6 million and no debt.  During the quarter, capital expenditures totaled $7.8 million, primarily due to costs related to the assumed facilities lease from Charles River as part of the asset acquisition, and investment on renovation of a new building dedicated to one of our major customers. During full year 2011, capital expenditures totaled $31.2 million, in line with our annual guidance released in previous quarters.

      Full Year 2012 Guidance

      For the full year 2012, the Company expects:

      • Net revenues to be approximately $131.7 – $136.2 million, which represents growth of approximately 18.0% – 22.0% compared with full year 2011. 
      • Non-GAAP gross margin to be approximately 31.5% – 33.5%, which is slightly lower than non-GAAP gross margin of 34.3% in 2011, based on the consideration of the increased costs related to our expanded facilities such as rental, utility and depreciation, and continued appreciation of the Renminbi.
      • Capital expenditures to be $20.0 - $24.0 million.

      This reflects the Company's current view and is subject to change.

      Conference Call

      ShangPharma will host a conference call and live webcast at 8am New York time on March 12, 2012 (8pm Beijing time on March 12, 2012).

      The dial-in details for the live conference call are as follows:

       

      - International:                                                                

      +1-718-354-1231

       

       

      - United States:

      +1-866-519-4004  

      - United Kingdom:

      +080-8234-6646

      - Hong Kong:

      +852-2475-0994

       

       

       

      Passcode:  SHP

       

      A live and archived webcast of the conference call will be available on the Investor Relations section of ShangPharma's website at www.shangpharma.com

      A telephone replay of the call will be available for seven days from March 12, 2012, 11:00AM U.S. Eastern Time to March 19, 2012, 11:59PM U.S. Eastern Time.

      The dial-in details for the replay are as follows:

        - International: +61-2-8235-5000
        - Passcode: 57079920

      ABOUT SHANGPHARMA CORPORATION

      ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

      Safe Harbor: Forward-Looking Statements

      This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Among other things, the section titled "Full Year 2012 Guidance" and quotations from management in this press release, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished with the U.S. Securities and Exchange Commission, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may have a material adverse effect on the Company's financial condition and results of operations for one or more periods. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained, either expressly or impliedly, in any of the forward-looking statements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

      About Non-GAAP Financial Measures

      To supplement the Company's consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the Company uses the following non-GAAP financial measures: (1) gross profit, (2) gross margin, (3) profit from operations, (4) operating expenses, (5) operating margin, (6) net income, and (7) diluted earnings per ADS, each of which excludes expenses relating to or the effect of share-based compensation and IPO bonuses. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and non-GAAP Financial Data" set forth at the end of this press release.

      The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its operating performance by excluding expenses relating to or the effect of share-based compensation and IPO bonuses that may not be indicative of its operating performance. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its operating performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The Company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using non-GAAP financial measures excluding expenses relating to or the effect of share-based compensation is that these expenses and effects have been and will continue to be significant recurring expenses in the Company's business for the foreseeable future. Management compensates for these limitations by providing specific information regarding the GAAP amount excluded from each non-GAAP measure. The accompanying tables have more details on the reconciliation between non-GAAP financial measures and their most comparable GAAP financial measures.

      For further information, please contact:

      ShangPharma Corporation
      Lan Xie
      VP of Finance and Operations
      E-mail: [email protected]

      Brunswick Group   
      Josh Gartner
      E-mail:[email protected]
      Phone: 86-10-5960-8600

      SHANGPHARMA CORPORATION
      UNAUDITED CONSOLIDATED BALANCE SHEET
      (in thousands of U.S. dollars, except for ordinary share data)

       

       

      December 31, 

      December 31, 

       

      2010

      2011

       

       

       

      ASSETS

       

       

      Current assets:

       

       

        Cash and cash equivalents

      49,160

      38,635

        Restricted cash

      688

      697

        Accounts receivable, net

      16,908

      24,246

        Amounts due from related parties

      -

      503

        Inventories

      1,259

      2,842

        Prepayments and other current assets

      4,779

      5,450

        Deferred tax assets

      315

      25

      Total current assets

      73,109

      72,398

      Non-current assets:

       

       

        Derivative assets

      261

      7

        Property, plant, equipment and software, net

      60,147

      86,521

        Land use right, net

      4,221

      6,634

        Other long-term assets

      204

      784

        Deferred tax assets

      -

      648

      Total non-current assets

      64,833

      94,594

      Total assets

      137,942

      166,992

       

       

       

      LIABILITIES

       

       

      Current liabilities:

       

       

        Short-term bank borrowings

      755

      -

        Accounts payable

      10,549

      16,306

        Amounts due to related parties

      1,025

      123

        Salary and welfare payable

      4,040

      3,863

        Income tax payable

      1,910

      2,919

        Advance from customers

      1,650

      1,868

      Other payables and accruals

      4,477

      8,734

      Total current liabilities

      24,406

      33,813

      Total liabilities

      24,406

      33,813

      Commitments and contingencies

       

       

       

       

       

      EQUITY

       

       

      Ordinary shares (US$0.001 par value; 429,999,350 shares authorized;
      335,600,000 and 336,109,400 shares issued and outstanding as of
      December 31, 2010 and December 31, 2011, respectively)

      336

      336

      Additional paid in capital

      78,989

      84,942

      Statutory reserves

      6,795

      8,317

      Retained earnings

      23,655

      33,372

      Accumulated other comprehensive income

      3,761

      7,304

         Less: Treasury stock

      -

      (1,092)

      Total equity

      113,536

      133,179

      Total liabilities and equity

      137,942

      166,992


       

       

      SHANGPHARMA CORPORATION
      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
      (in thousands of U.S. dollars, except for ADS[1] data and per ADS data)

       

       

       

      Three months ended

      Twelve months ended

       

      December 31,

      December 31,

       

      2010

      2011

      % Change

      2010

      2011

      % Change

       

       

       

       

       

       

       

      Net revenue

      25,609

      30,484

      19.0%

      90,281

      111,602

      23.6%

      Cost of revenue

      (17,345)

      (20,527)

      18.3%

      (60,168)

      (75,503)

      25.5%

      Gross profit

      8,264

      9,957

      20.5%

      30,113

      36,099

      19.9%

       

       

       

       

       

       

       

      Operating expenses

       

       

       

       

       

       

           Selling and marketing

      (703)

      (925)

      31.6%

      (2,293)

      (2,640)

      15.1%

           General and administrative

      (6,645)

      (6,854)

      3.1%

      (17,429)

      (23,961)

      37.5%

           Other operating income[2]

      -

      203

       

      -

      360

       

           Other operating expenses[2]

      -

      (90)

       

      -

      (194)

       

      Total operating expenses

      (7,348)

      (7,666)

      4.3%

      (19,722)

      (26,435)

      34.0%

       

       

       

       

       

       

       

      Profit from operations

      916

      2,291

      150.1%

      10,391

      9,664

      -7.0%

       

       

       

       

       

       

       

      Other income, net:

      2,263

      623

      -72.5%

      4,691

      3,894

      -17.0%

      Income from operations before income
      taxes

      3,179

      2,914

      -8.3%

      15,082

      13,558

      -10.1%

       

       

       

       

       

       

       

      Income taxes

      (633)

      (632)

      -0.2%

      (2,085)

      (2,319)

      11.2%

      Net income 

      2,546

      2,282

      -10.4%

      12,997

      11,239

      -13.5%

       

       

       

       

       

       

       

      Allocation to preferred shareholders

      (108)

      -

      -100.0%

      (2,739)

      -

      -100.0%

      Net income attributable to ordinary
      shareholders

      2,438

      2,282

      -6.4%

      10,258

      11,239

      9.6%

       

       

       

       

       

       

       

      Net income attributable to ordinary
      shareholders per ADS 

       

       

       

       

       

       

           Basic

      0.14

      0.12

      -14.3%

      0.79

      0.60

      -24.1%

           Diluted

      0.14

      0.12

      -14.3%

      0.78

      0.60

      -23.1%

       

       

       

       

       

       

       

      Weighted average ADS outstanding

       

       

       

       

       

       

           Basic

      17,257,553

      18,602,842

       

      12,993,020

      18,641,023

       

           Diluted

      17,563,304

      18,602,842

       

      13,222,233

      18,771,403

       

       

      [1] Assumes all outstanding ordinary shares are represented by ADSs. Each ADS represents 18 ordinary shares.

      [2] Certain government subsidies and the related costs were reclassified to other operating profits since the third quarter of 2011 as a result of an accounting policy change to better reflect the nature of such transactions.

      The change in accounting policy was not retroactively applied due to immateriality.

       

       

      SHANGPHARMA CORPORATION
      RECONCILIATION OF UNAUDITED GAAP TO NON-GAAP FINANACIAL DATA
      (in thousands of U.S. dollars, except for ADS[2] data and per ADS data)

       

       

       

      Three months ended

      Twelve months ended

       

      December 31,

      December 31,

       

      2010

      2011

      %

      2010

      2011

      %

      GAAP gross profit

      8,264

      9,957

      20.5%

      30,113

      36,099

      19.9%

      GAAP gross margin

      32.3%

      32.7%

       

      33.4%

      32.3%

       

      Adjustments:

       

       

       

       

       

       

          Share-based compensation

      557

      516

      -7.4%

      1,003

      2,147

      114.1%

      Non-GAAP gross profit

      8,821

      10,473

      18.7%

      31,116

      38,246

      22.9%

      Non-GAAP gross margin

      34.4%

      34.4%

       

      34.5%

      34.3%

       

       

       

       

       

       

       

       

      GAAP operating expenses

      (7,348)

      (7,666)

      4.3%

      (19,722)

      (26,435)

      34.0%

      Adjustments:

       

       

       

       

       

       

          Share-based compensation

      2,798

      1,186

      -57.6%

      2,980

      4,081

      36.9%

      Non-GAAP operating expenses

      (4,550)

      (6,480)

      42.4%

      (16,742)

      (22,354)

      33.5%

       

       

       

       

       

       

       

      GAAP profit from operations

      916

      2,291

      150.1%

      10,391

      9,664

      -7.0%

      GAAP operating margin

      3.6%

      7.5%

       

      11.5%

      8.7%

       

      Adjustments:

       

       

       

       

       

       

          IPO bonuses

      235

      -

      -100.0%

      235

      -

      -100.0%

          Share-based compensation

      3,120

      1,702

      -45.4%

      3,748

      6,228

      66.2%

      Non-GAAP profit from operations

      4,271

      3,993

      -6.5%

      14,374

      15,892

      10.6%

      Non-GAAP operating margin

      16.7%

      13.1%

       

      15.9%

      14.2%

       

       

       

       

       

       

       

       

      GAAP net income

      2,546

      2,282

      -10.4%

      12,997

      11,239

      -13.5%

      GAAP net margin

      9.9%

      7.5%

       

      14.4%

      10.1%

       

      Adjustments:

       

       

       

       

       

       

          Share-based compensation

      3,355

      1,702

      -49.3%

      3,983

      6,228

      56.4%

      Non-GAAP net income

      5,901

      3,984

      -32.5%

      16,980

      17,467

      2.9%

      Non-GAAP net margin 

      23.0%

      13.1%

       

      18.8%

      15.7%

       

       

       

       

       

       

       

       

      GAAP net income attributable to ordinary
      shareholders per ADS, diluted:

      0.14

      0.12

      -14.3%

      0.78

      0.60

      -23.1%

      Adjustments:

       

       

       

       

       

       

          Share-based compensation

      0.18

      0.09

       

      0.29

      0.33

       

      Non-GAAP net income attributable to
      ordinary shareholders per ADS, diluted:

      0.32

      0.21

      -34.4%

      1.07

      0.93

      -13.1%

       

       

       

       

       

       

       

      Weighted average ADS outstanding - basic
      (Non-GAAP)

      17,257,553

      18,602,842

       

      12,993,020

      18,641,023

       

      Weighted average ADS outstanding - diluted
      (Non-GAAP)

      17,563,304

      18,602,842

       

      13,222,233

      18,771,403

       

       

       

       

       

      [2] Assumes all outstanding ordinary shares are represented by ADSs. Each ADS represents 18 ordinary shares.

       

       

       


      SOURCE ShangPharma Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.